Clinical trials: Radioligand
Depression
A Study of Nociceptin/Orphanin FQ Peptide Receptor Occupancy in Healthy Subjects
The purpose of this trial is to conduct an assessment of brain nociceptin/orphanin FQ peptide (NOP) receptor occupancy (RO) in healthy subjects.
- Trial name
- NCT01404091
- Testing
- LY2940094
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- BlackThorn Therapeutics, Inc.
Parkinson Disease
Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers
This study investigates the initial safety profile of [18F]P17-059 in healthy volunteers including dosimetry determination, and compares regional brain uptake and kinetics of [18F]P17-059 in Parkinson's disease patients with…
- Trial name
- NCT03903549
- Testing
- [18F]P17-059
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Five Eleven Pharma, Inc.
Healthy
A Study of LY3857210 in Healthy Participants
The main purpose of this study is to evaluate the presence of study drug LY3857210 in the brain measured by positron emission tomography (PET) with the radioligand [18F]-LY3818850 in healthy participants.
- Trial name
- NCT05292040
- Testing
- LY3857210
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Maximum Diagnostic Mass of [18Fluor]AZD4694
An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease
In this study different mass of the radioligand AZD4694 will be given to patients with Alzheimer's Disease and healthy volunteers to evaluate wich Mass of AZD4694 that gives the best opportunities for following disease progress…
- Trial name
- NCT01325402
- Testing
- [18Fluor]AZD4694
- Where
- 2 sites in Sweden
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Major Depressive Disorder
An Open-label, Adaptive Design, Positron Emission Tomography Study in Healthy Male Participants to Characterize Receptor Occupancy by MIJ821 in the Brain
The purpose of this study is to confirm binding of MIJ821 to the NR2B-containing NMDA receptors in the human brain and assess the PC-RO relationship over time using positron emission tomography (PET).
- Trial name
- NCT05666687
- Testing
- MIJ821
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer (Adenocarcinoma), Prostate Biopsy
RegisterPROS - A Registry for Prostate Cancers
Prostate cancers are derived from epithelial cells in the prostate gland. Treatment options include surgery, medical (androgen signaling targeted and chemotherapy) and radiation therapy including radioligand therapy (RLT).
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate Biopsy, Prostatectomy, Radioligand
- Trial name
- RegisterPROS (NCT06872619)
- Testing
- PROSTest
- Where
- Germany
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Wren Laboratories LLC
Multiple Sclerosis
[18F]PBR111 and Microglial Activation in Multiple Sclerosis
This is a study aimed to characterize [18F]PBR111 as an in vivo marker of microglial activation in Multiple Sclerosis. Regional binding of [18F]PBR111 will be quantified with PET in the brain of up to 24 patients with multiple…
- Trial name
- NCT01428505
- Testing
- [18F]PBR111
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study of the Effects of Multiple Doses of LY3372689 on the Brain in Healthy Participants
This study uses imaging to evaluate how LY3372689 binds to a protein in the brain. This study will be conducted in healthy participants and will last up to about 10 weeks.
- Trial name
- NCT04392271
- Testing
- LY3372689, [18F]LSN3316612
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Parkinsonian Syndrome, Parkinson Disease(PD)
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
This is a multicenter, open-label, non-controlled, non-randomized, phase 3 clinical study to compare the SPECT findings after a single IV administration of DaTSCAN™ ioflupane (123I) injection for patients with a clinical…
- Conditions
- Parkinsonian Syndrome, Parkinson Disease(PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP)
- Trial name
- NCT04193527
- Testing
- DaTSCAN™ Ioflupane (123I) Injection
- Where
- 10 sites in China
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Brain Distribution of [11C]AZ12807110 and AZD5213
Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration
The purpose of this study is to investigate features of radioligand [11C]AZ12807110 and how much AZD5213 displaces radioligand from histamine receptors when given together.
- Trial name
- NCT01194986
- Testing
- [11C]AZ12807110, AZD5213
- Where
- Sweden
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Alzheimer's Disease
Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
This is an open-label, longitudinal observational study evaluating the imaging characteristics of the tau positron-emission tomography (PET) radioligand [18F] Genentech Tau Probe 1 (GTP1) in the brain of participants with…
- Trial name
- NCT02640092
- Testing
- [18F]GTP1
- Where
- 16 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Progressive Supranuclear Palsy
Test-retest Study With [18F]PI-2620 in PSP-RS and NDC
The overall goal of this protocol is to evaluate the imaging characteristics of [18F]PI-2620 using positron emission tomography (PET) in patients with progressive supranuclear palsy, Richardson's syndrome (PSP-RS)
- Trial name
- NCT05187546
- Testing
- [18F]-PI2620
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Life Molecular Imaging GmbH
Parkinson Disease (PD), MSA - Multiple System Atrophy
Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot Phase
This is an open-label, single-center Phase 1 study evaluating the safety, tolerability, and test-retest characteristics of [11C]MODAG-005, an investigational positron emission tomography/computed tomography (PET/CT) radioligand…
- Conditions
- Parkinson Disease (PD), MSA - Multiple System Atrophy, Healthy Adult Participants
- Trial name
- PIOSA (NCT07640542)
- Testing
- [11C]MODAG-005
- Where
- Germany
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS)
[18F]ACI-19626 PET in TDP-43 Proteinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein TDP-43 [involved in rare forms of dementia such as frontotemporal dementia (FTD) and in amyotrophic…
- Conditions
- Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS), TDP-43 Proteinopathies, Suspected Limbic Predominant Age-related TDP-43 Encephalopathy (LATE)
- Trial name
- NCT06891716
- Testing
- [18F]ACI-19626
- Where
- Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Healthy, Alzheimer Disease
A Non-therapeutic Feasibility Study of the Radioligand [11C]-UCB-J for Imaging Synaptic Density
Up to 20 subjects will receive an injection with [11C]-UCB-J followed by a PET scan on Days 1 and 28
- Trial name
- NCT03577262
- Testing
- [11C]-UCB-J
- Where
- 3 sites in Netherlands
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Alkermes, Inc.
Healthy
A Study of the Effects of LY3372689 on the Brain in Healthy Participants
This study uses imaging to evaluate how LY3372689 binds to a protein in the brain. This study will be conducted in healthy participants and will last up to approximately 25 days after enrollment.
- Trial name
- NCT03944031
- Testing
- LY3372689, [18F]LSN3316612
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alcohol Dependence
A Study of Brain Receptor Occupancy in Healthy Subjects
To measure the occupancy of brain kappa opioid receptors after single oral doses of LY2456302.
- Trial name
- NCT01232439
- Testing
- opioid receptor kappa antagonist
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Parkinson's Disease (PD), Multiple System Atrophy (MSA)
[18F]ACI-15916 PET in α-synucleinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein α-synuclein [involved in some diseases such as Parkinson's disease, Lewy body dementia and Multiple…
- Conditions
- Parkinson's Disease (PD), Multiple System Atrophy (MSA), Dementia With Lewy Bodies (DLB)
- Trial name
- NCT06891703
- Testing
- [18F]ACI-15916
- Where
- Sweden
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- AC Immune SA